1. Home
  2. GANX vs BDL Comparison

GANX vs BDL Comparison

Compare GANX & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • BDL
  • Stock Information
  • Founded
  • GANX 2017
  • BDL 1959
  • Country
  • GANX United States
  • BDL United States
  • Employees
  • GANX N/A
  • BDL N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • BDL Restaurants
  • Sector
  • GANX Health Care
  • BDL Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • BDL Nasdaq
  • Market Cap
  • GANX 53.4M
  • BDL 57.7M
  • IPO Year
  • GANX 2021
  • BDL N/A
  • Fundamental
  • Price
  • GANX $1.92
  • BDL $30.50
  • Analyst Decision
  • GANX Strong Buy
  • BDL
  • Analyst Count
  • GANX 5
  • BDL 0
  • Target Price
  • GANX $8.00
  • BDL N/A
  • AVG Volume (30 Days)
  • GANX 378.4K
  • BDL 729.0
  • Earning Date
  • GANX 08-12-2025
  • BDL 08-12-2025
  • Dividend Yield
  • GANX N/A
  • BDL 1.82%
  • EPS Growth
  • GANX N/A
  • BDL 41.91
  • EPS
  • GANX N/A
  • BDL 2.32
  • Revenue
  • GANX N/A
  • BDL $201,851,000.00
  • Revenue This Year
  • GANX N/A
  • BDL N/A
  • Revenue Next Year
  • GANX N/A
  • BDL N/A
  • P/E Ratio
  • GANX N/A
  • BDL $13.12
  • Revenue Growth
  • GANX N/A
  • BDL 8.84
  • 52 Week Low
  • GANX $0.95
  • BDL $22.61
  • 52 Week High
  • GANX $3.19
  • BDL $35.98
  • Technical
  • Relative Strength Index (RSI)
  • GANX 61.71
  • BDL 45.10
  • Support Level
  • GANX $1.65
  • BDL $30.00
  • Resistance Level
  • GANX $2.07
  • BDL $31.34
  • Average True Range (ATR)
  • GANX 0.16
  • BDL 0.41
  • MACD
  • GANX 0.05
  • BDL -0.06
  • Stochastic Oscillator
  • GANX 70.15
  • BDL 14.66

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

Share on Social Networks: